Pelareorep Completed Phase 2 Trials for Non-Small Cell Lung Carcinoma Treatment

Indications	Status	Purpose	Phase
DBCOND0030527 (Non-Small Cell Lung Carcinoma)	Completed	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT00861627	Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation	Carboplatin (DB00958) Paclitaxel (DB01229) Pelareorep (DB17284)